AVITA Medical

RCELApproved

Valencia, United StatesFounded 1992avitamedical.com

AVITA Medical is a commercial-stage regenerative medicine company focused on transforming acute wound care through its proprietary autologous cell harvesting technology. Its FDA-approved RECELL System is the cornerstone of a platform designed to harness a patient's own skin for healing, with applications expanding beyond burns into traumatic and surgical wounds. The company is actively advancing its pipeline through clinical trials, supported by a commercial infrastructure in the U.S. and international approvals, aiming to improve clinical outcomes and reduce healthcare costs. AVITA's strategy centers on leveraging its core technology across multiple indications while commercializing a portfolio of advanced wound care products.

Market Cap

$121.0M

Founded

1992

Focus

Regenerative MedicineDermatology

RCEL · Stock Price

USD 3.953.58 (-47.54%)

Historical price data

AI Company Overview

Technology Platform

The RECELL® System is an autologous cell harvesting platform that uses a small sample of a patient's skin to create a suspension of Spray-On Skin™ Cells at the point of care for regenerative healing.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage	Watch
ReCell	Carbon Dioxide Laser	Approved

Funding History

Total raised: $55M

PIPE$40MUndisclosedSep 15, 2020

IPO$15MUndisclosedDec 12, 2012

Opportunities

Significant growth opportunities exist through the expansion of the RECELL System's label into broader traumatic and surgical wound indications, which represent a much larger patient population than burns alone.

The commercialization of the simplified RECELL GO Mini device and the demonstration of cost-effectiveness in active clinical trials can drive deeper market penetration and hospital adoption.

Leveraging the existing commercial channel to cross-sell the integrated portfolio of RECELL, PermeaDerm, and Cohealyx presents a synergistic revenue opportunity.

Risk Factors

Key risks include commercial execution challenges in a competitive wound care market, potential delays or negative outcomes in pivotal clinical trials for label expansions, and reliance on securing and maintaining favorable insurance reimbursement.

The company also faces financial risk if revenue growth does not outpace operating expenses, potentially requiring dilutive capital raises.

The current interim CEO status adds a layer of strategic uncertainty.

Competitive Landscape

AVITA competes with traditional skin grafting, companies offering cultured epidermal autografts (e.g., Vericel's Epicel), and major players in biological/synthetic skin substitutes (e.g., Integra, Smith & Nephew). Its primary differentiation is the RECELL System's point-of-care, autologous cell harvesting, which provides immediate regenerative therapy without the weeks-long culturing process required by alternatives, offering potential operational and cost advantages.